ViroPharma to buy Lev for $442M

ViroPharma has forged a deal to buy Lev Pharmaceuticals--a developer focused on developing inflammatory therapies--for $442 million. The deal provides ViroPharma with Lev's Cinryze program, a late-stage therapy under FDA review as a replacement therapy for hereditary angioedema. ViroPharma will pay $2.25 per share in cash and 50 cents per share in stock.

"This transaction is consistent with ViroPharma's stated objective of broadening our portfolio of therapies for serious life-threatening conditions in selected specialty markets," commented Vincent Milano, ViroPharma's president and chief executive officer. "We are very pleased to add the expertise of Lev to our organization, and Cinryze to our growing portfolio of options for underserved patient populations with critical and urgent needs."

- check out the buyout release

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.